June 15, 2026 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
June 15, 2026 OpportunityZones.com Publishes The Opportunity Zones Playbook, the First Comprehensive Guide to OZ 2.0 by Jimmy Atkinson
June 15, 2026 Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
